Key Points
- L1 Capital Pty Ltd bought 648,455 AVR shares at an average of $7.51, investing approximately $4.87 million and increasing its stake by 5.35% to 12.78 million shares.
- Anteris Technologies Global reported a quarterly loss of $0.30 per share, missing estimates by $0.09, while revenue of $1.01 million also fell short of expectations.
- Analyst sentiment remains generally positive, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $14, compared with the reported $7.05 share price.
Anteris Technologies Global Corp. (NASDAQ:AVR - Get Free Report) major shareholder L1 Capital Pty Ltd bought 236,354 shares of the firm's stock in a transaction dated Friday, October 2nd. The shares were acquired at an average price of $7.78 per share, for a total transaction of $1,838,834.12. Following the acquisition, the insider directly owned 12,129,925 shares of the company's stock, valued at approximately $94,370,816.50. The trade was a 1.99% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
L1 Capital Pty Ltd also recently made the following trade(s):
- On Monday, October 5th, L1 Capital Pty Ltd purchased 648,455 shares of Anteris Technologies Global stock. The stock was acquired at an average cost of $7.51 per share, with a total value of $4,869,897.05.
- On Thursday, October 1st, L1 Capital Pty Ltd purchased 322,940 shares of Anteris Technologies Global stock. The stock was acquired at an average cost of $7.60 per share, with a total value of $2,454,344.00.
- On Wednesday, September 30th, L1 Capital Pty Ltd purchased 74,286 shares of Anteris Technologies Global stock. The shares were bought at an average price of $7.72 per share, for a total transaction of $573,487.92.
- On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.83, for a total transaction of $68,874.00.
- On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.30, for a total transaction of $3,495,079.50.
- On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.10, for a total transaction of $2,291,780.40.
- On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total transaction of $1,415,240.10.
- On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.30, for a total transaction of $3,989,046.40.
- On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.23, for a total transaction of $120,001.63.
- On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.10, for a total transaction of $3,853,113.30.
Anteris Technologies Global Price Performance
Shares of Anteris Technologies Global stock opened at $7.05 on Wednesday. The firm has a market cap of $687.08 million, a P/E ratio of -3.62 and a beta of 1.87. The firm has a 50 day simple moving average of $8.46 and a 200 day simple moving average of $8.01. Anteris Technologies Global Corp. has a fifty-two week low of $3.30 and a fifty-two week high of $11.06.
Anteris Technologies Global (NASDAQ:AVR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.09). The firm had revenue of $1.01 million for the quarter, compared to analyst estimates of $1.50 million. Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%.During the same period in the prior year, the company posted ($0.58) EPS. On average, sell-side analysts expect that Anteris Technologies Global Corp. will post -1.21 EPS for the current year.
Institutional Trading of Anteris Technologies Global
Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new position in shares of Anteris Technologies Global in the 2nd quarter valued at $78,000. Abel Hall LLC acquired a new stake in shares of Anteris Technologies Global during the first quarter worth $63,000. Bartlett & CO. Wealth Management LLC grew its stake in shares of Anteris Technologies Global by 174.5% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company's stock worth $79,000 after purchasing an additional 8,200 shares during the period. One68 Global Capital LLC bought a new stake in Anteris Technologies Global in the second quarter valued at about $128,000. Finally, J. Derek Lewis & Associates Inc. bought a new stake in Anteris Technologies Global in the fourth quarter valued at about $70,000.
Key Headlines Impacting Anteris Technologies Global
Here are the key news stories impacting Anteris Technologies Global this week:
- Positive Sentiment: Major shareholder increased its stake. L1 Capital bought 648,455 shares at an average of $7.51, worth approximately $4.87 million, increasing its position by 5.35% to 12.78 million shares. The investor also purchased 236,354 shares on October 2 and additional shares in late September and early October, bringing recent buying to roughly 1.28 million shares worth $9.7 million. This may support investor confidence because a large shareholder is committing substantial capital despite recent weakness. Anteris Technologies Global insider buying report
- Positive Sentiment: Analyst coverage is generally favorable. Barclays initiated coverage with a positive rating and a $10 price target, while Cantor Fitzgerald maintained an overweight rating and a $15 target. The reported consensus rating is “Moderate Buy,” with an average target of $14, substantially above the recent trading level. Anteris Technologies Global analyst and stock report
- Neutral Sentiment: Share and equity-incentive records were updated. Anteris reported a slight decrease in CHESS Depositary Interests and the lapse or cessation of several restricted stock unit and option tranches. The changes may affect the share count and potential dilution, but the filings did not indicate a new operating or clinical catalyst. Anteris Technologies CDI and equity incentive update
- Negative Sentiment: Fundamentals remain weak. The latest quarterly results missed expectations, with a $0.30 per-share loss versus the forecast $0.21 loss and revenue of $1.01 million versus the $1.50 million estimate. Anteris remains unprofitable, and analysts expect a full-year loss. Shares also remain below their 50-day and 200-day moving averages, reflecting continued technical pressure. Anteris Technologies Global earnings and performance report
Wall Street Analyst Weigh In
Several equities analysts have recently issued reports on AVR shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Barclays assumed coverage on Anteris Technologies Global in a research report on Tuesday. They issued a "positive" rating and a $10.00 price objective for the company. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $15.00 target price on shares of Anteris Technologies Global in a research report on Friday, August 14th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Anteris Technologies Global presently has a consensus rating of "Moderate Buy" and a consensus target price of $14.00.
Read Our Latest Stock Report on Anteris Technologies Global
About Anteris Technologies Global
(
Get Free Report)
Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company's lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.
Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.
The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
